Chemical Computing Market Research Report

According to data analyzed by Insightorax, the global chemical computing market size was valued at USD 0.9 billion in 2026 and is projected to grow from USD 1.0 billion in 2027 to USD 2.8 billion by 2035, registering a CAGR of 14.2% during the 2026–2035 forecast period. Asia Pacific accounted for the largest revenue share of 34.5% in 2026. Global growth is driven by increasing adoption of computational chemistry in drug discovery, materials development, and chemical research, alongside advances in artificial intelligence, machine learning, molecular modeling, and high-performance computing. Rising pharmaceutical R&D spending, demand for faster molecular simulation, growing need to reduce laboratory costs and development timelines, and increasing use of cloud-based chemical computing platforms are major demand factors supporting market expansion.

The Chemical Computing Market encompasses software, computational platforms, algorithms, and related technologies used to model, simulate, analyze, and predict chemical structures, reactions, molecular behavior, and material properties. It supports computational chemistry and digital workflows across pharmaceutical, biotechnology, chemicals, materials science, academic research, and industrial R&D. The market covers solutions that help researchers evaluate molecular interactions, optimize compounds, predict chemical properties, and accelerate research and development activities.

Key components include molecular modeling and simulation, quantum chemistry, molecular dynamics, cheminformatics, computational drug discovery, chemical databases, reaction prediction, AI- and machine-learning-based chemical analysis, and high-performance or cloud computing infrastructure. The market also includes software platforms, computational tools, data-management capabilities, and associated services. Its scope extends across research institutions, pharmaceutical and biotechnology companies, chemical manufacturers, materials developers, and other organizations seeking faster, more accurate, and cost-efficient computational approaches to chemical discovery and development.

The Chemical Computing Market has evolved from traditional computational chemistry and molecular modeling tools into advanced digital platforms supporting complex chemical analysis, simulation, and prediction. Early adoption was concentrated in academic research and pharmaceutical R&D, where computational methods helped reduce laboratory experimentation and improve compound screening. Increasing computing capabilities, larger chemical datasets, and integration of artificial intelligence have broadened applications across drug discovery, materials science, specialty chemicals, and industrial research.

The market is expanding as organizations seek faster and more cost-efficient approaches to chemical discovery and development. Growing pharmaceutical and biotechnology R&D, demand for accurate molecular simulations, increasing adoption of cloud and high-performance computing, and advances in AI-driven chemical modeling are strengthening adoption. Future expansion is expected to be supported by greater automation, improved computational accuracy, expanding chemical databases, and wider integration of computational workflows with laboratory and industrial processes.

Key Market Trends & Insights

• By component: Software segment dominated the market with a 55.4% share in 2026.
• By technology: Molecular Computing segment led the market in terms of share, accounting for 30.1% in 2026.
• By deployment mode: Cloud-based segment commanded the largest market share at 48.8% in 2026.
• By application: Drug Discovery & Development segment accounted for the highest market share of 33.8% in 2026.
• By end user: Pharmaceuticals & Biotechnology segment maintained a leading position in the market, holding a 35.1% share in 2026.

Regional Highlights

• Largest regional market: Asia Pacific (34.5% revenue share, 2026)
• Fastest-growing regional market: Asia Pacific (Highest CAGR: 15.8%, 2026–2035)
• By country: United States held the largest market share in 2026

Market Size & Forecast

• Market size in 2026: USD 0.9 Billion
• Estimated market size in 2027: USD 1.0 Billion
• Projected market size by 2035: USD 2.8 Billion
• CAGR (2026-2035): 14.2%

The Chemical Computing Market is driven by the growing use of computational methods in drug discovery, molecular design, materials development, and chemical research. Increasing pharmaceutical and biotechnology R&D, demand for faster compound screening, rising adoption of artificial intelligence and machine learning, and advances in high-performance and cloud computing are accelerating market adoption. Growing chemical datasets and the need to reduce development costs, laboratory experimentation, and research timelines are further supporting demand for advanced computational tools.

However, market expansion faces challenges including high implementation costs, limited availability of specialized computational chemistry expertise, complex software integration, and difficulties in managing and standardizing large chemical datasets. Computational accuracy and model validation also remain important concerns, particularly when simulations and AI-generated predictions are used for critical research and development decisions. Data security, interoperability, and the complexity of integrating computational platforms with existing laboratory workflows can further restrict adoption among smaller organizations.

Significant opportunities exist through the integration of generative AI, machine learning, quantum computing, and automated molecular simulation into chemical computing platforms. Cloud-based solutions can expand access by reducing infrastructure requirements and enabling scalable computational resources. Growing demand for digital drug discovery, sustainable materials, advanced catalysts, and process optimization creates additional opportunities. Partnerships among software providers, pharmaceutical companies, chemical manufacturers, research institutions, and technology developers can further accelerate innovation and broaden market applications.

The Chemical Computing Market is increasingly shaped by AI-enabled computational chemistry, machine learning, and generative models that accelerate molecular property prediction, reaction analysis, compound screening, and chemical design. In 2025–2026, agentic AI workflows are emerging to automate computational chemistry tasks, while multimodal models combine different molecular data types to improve prediction performance. Machine-learning interatomic potentials are also gaining attention for bridging quantum-level accuracy with faster simulation.

Regionally, adoption is strengthening across North America, Europe, and Asia-Pacific, supported by pharmaceutical R&D, materials innovation, advanced computing infrastructure, and expanding chemical datasets. Materials discovery is becoming an important application, with generative AI increasingly used to propose crystal structures and predict properties. The availability of large datasets, including new molecular-crystal resources, is supporting development of more capable computational models and accelerating digital experimentation.

Regulatory focus is also increasing as computational and AI models become more involved in drug development. In 2025–2026, regulators emphasized risk-based evaluation, reliability, transparency, and validation of AI-generated evidence used in pharmaceutical decision-making. Industry trends increasingly favor explainable models, automated workflows, cloud-based computing, physics-informed AI, and integration between simulation and laboratory systems. These developments are encouraging chemical companies and life-science organizations to adopt computational platforms that improve research efficiency while maintaining reproducibility and scientific validation.

The Chemical Computing Market operates within broader chemical-safety, pharmaceutical, and digital-modeling requirements. In the European Union, REACH requires chemical risks to be identified and managed, while CLP establishes requirements for classification, labeling, and packaging of hazardous substances and mixtures. The EU’s “one substance, one assessment” framework, effective from January 2026, aims to make chemical assessments more consistent and transparent.

For pharmaceutical applications, computational models used in development are increasingly addressed through harmonized regulatory guidance. The ICH M15 guideline, adopted in January 2026, establishes general principles and good practices for Model-Informed Drug Development, including expectations for model documentation and use. Chemical-computing platforms supporting regulated research therefore increasingly require traceability, validation, reproducibility, appropriate documentation, and scientifically justified model use.

The Chemical Computing Market has an indirect but growing role in sustainability by enabling computational screening before physical experimentation. Chemical modeling can help evaluate safer molecules, reaction pathways, solvents, catalysts, and process conditions while reducing unnecessary laboratory trials, material consumption, and waste. EPA’s green chemistry framework emphasizes pollution prevention, resource efficiency, safer feedstocks, energy efficiency, and lifecycle considerations in chemical design. Computational tools such as GREENSCOPE can also assess material, energy, environmental, and economic performance during process development.

Environmental challenges include the energy consumption and infrastructure requirements associated with large-scale computing, alongside the broader environmental footprint of chemical manufacturing, sourcing, packaging, transportation, and distribution. Industry initiatives increasingly connect computational modeling with sustainable process design and lifecycle assessment. The ACS Green Chemistry Institute recognizes computational tools that reduce process mass intensity, waste, safety impacts, and resource use, while EPA programs promote computer-based models for safer chemical development and pollution prevention.

Software accounted for 55.4% of revenue in 2026, reflecting its central role in translating chemical processes into computational models and functional applications. Specialized software supports molecular simulation, reaction modelling, chemical data analysis, algorithm development, and the interpretation of complex interactions. Growing interest in computational chemistry and alternative computing architectures is encouraging demand for platforms capable of processing intricate chemical information efficiently. Integration with artificial intelligence, advanced analytics, and simulation environments further strengthens software's commercial relevance. As research organizations and industrial users seek more accurate modelling capabilities, software solutions remain essential for developing, testing, and scaling chemical computing applications across scientific and commercial environments.

Hardware represented 24.7% of revenue in 2026, supported by the need for specialized systems that execute and facilitate chemical computation. This category includes physical computing architectures, experimental equipment, and associated infrastructure required to operate chemical processing systems. Services also contribute through implementation, integration, technical support, maintenance, and specialized consulting. Together, these components support deployment across pharmaceuticals and biotechnology, academic research, materials science, and chemical manufacturing. Continued development of computing platforms and greater emphasis on operational reliability are expected to reinforce demand for coordinated hardware, software, and service capabilities, strengthening the technology's practical value for research-intensive organizations.

Molecular Computing held 30.1% of revenue in 2026, reflecting its potential to use molecular properties and interactions for information processing. Its relevance extends to complex scientific calculations, molecular modelling, and research involving chemical and biological systems. Interest in miniaturized computational architectures and alternative approaches to conventional electronics is encouraging investigation of molecular-scale processing. Advances in molecular design, experimental techniques, and interdisciplinary research could improve the feasibility of practical implementations. Pharmaceutical research, materials development, and computational chemistry provide important contexts for evaluating this technology's capabilities, particularly where molecular behaviour itself carries useful computational information.

DNA Computing represented 24.3% of revenue in 2026, benefiting from research into DNA molecules as information-storage and processing media. Its potential applications include complex problem-solving, molecular data handling, and specialized computational tasks involving biological structures. Reaction-diffusion systems, oscillating chemical reactions, and enzyme-based computing also contribute distinct approaches by exploiting chemical dynamics, reaction patterns, and biochemical processes. Progress depends on experimental reproducibility, processing efficiency, scalability, and integration with conventional computing infrastructure. Collectively, these technologies expand the range of computational methods available to researchers, although practical adoption remains closely linked to technical validation and the development of reliable implementation frameworks.

Drug Discovery & Development accounted for 33.8% of revenue in 2026, reflecting the importance of computational methods in pharmaceutical research. Chemical computing can support molecular interaction analysis, candidate screening, reaction modelling, and investigations into complex biochemical behaviour. These capabilities may help researchers evaluate compounds, explore molecular pathways, and prioritize experiments before undertaking resource-intensive laboratory procedures. Growing interest in accelerating research workflows and improving scientific understanding supports demand for advanced computational approaches. Pharmaceutical companies and biotechnology organizations are important prospective users, particularly where complex molecular systems create challenges for conventional analytical methods. The application also provides opportunities to connect computational chemistry with emerging experimental techniques.

Materials Science represented 20.2% of revenue in 2026, supported by demand for improved understanding of molecular structures, material properties, and chemical interactions. Computational approaches can assist researchers investigating novel compounds, functional materials, and performance characteristics relevant to industrial applications. Cryptography & Security, Pattern Recognition, and Chemical Synthesis Optimization broaden the application landscape through specialized computational tasks, analytical processing, and reaction-planning support. Adoption across these fields depends on computational accuracy, practical scalability, and compatibility with existing research workflows. Together, these applications demonstrate the technology's relevance beyond pharmaceutical discovery, creating opportunities for scientific innovation, improved process understanding, and more efficient experimentation across multiple research-intensive industries.

Pharmaceuticals & Biotechnology represented 35.1% of revenue in 2026, reflecting strong alignment between chemical computing capabilities and molecular research requirements. Organizations in this sector investigate complex biochemical interactions, evaluate potential therapeutic compounds, and develop increasingly sophisticated drug research workflows. Computational methods can complement laboratory experimentation by supporting molecular analysis, reaction modelling, and the exploration of biological systems. Demand is influenced by continuing pharmaceutical innovation, the need to investigate complex molecules, and efforts to improve research efficiency. These capabilities position chemical computing as a potentially valuable complement to conventional computational chemistry and experimental infrastructure throughout drug discovery and biotechnology development.

Academic & Research Institutions accounted for 24.8% of revenue in 2026, supported by interdisciplinary investigations spanning chemistry, biology, materials science, and emerging computing architectures. Universities and research laboratories contribute to foundational experimentation, technology validation, and the development of new computational methods. Defense & Intelligence, Chemical Manufacturing, and Healthcare & Diagnostics provide additional avenues for adoption, including specialized analytical research, process optimization, and diagnostic investigation. Their requirements differ according to operational priorities, technical maturity, and available infrastructure. Broader industry participation will depend on demonstrable performance, reproducibility, and integration with established workflows, while collaboration between commercial organizations and research institutions can help advance practical applications.

Cloud-based deployment represented 48.8% of revenue in 2026, reflecting demand for accessible computational resources and flexible research infrastructure. Cloud environments can support collaborative experimentation, scalable processing, centralized data management, and access to specialized software without requiring every organization to maintain extensive local computing resources. These characteristics are relevant to research teams handling complex molecular models or computationally intensive workloads. Flexible resource allocation can also help organizations accommodate changing project requirements and collaborate across locations. Adoption nevertheless depends on data protection, regulatory obligations, connectivity, and the suitability of cloud infrastructure for specialized chemical computing tasks.

On-premise deployment accounted for 27.2% of revenue in 2026, supported by organizations requiring direct infrastructure control, customized configurations, or closer management of sensitive research data. This approach can be relevant to pharmaceutical laboratories, industrial research facilities, and institutions operating under strict security or operational requirements. Hybrid deployment offers an alternative by combining local infrastructure with cloud resources, allowing users to balance control, flexibility, and computing capacity. Selection among these approaches depends on workload characteristics, budget considerations, data governance, and integration requirements. As implementations mature, deployment flexibility will remain important to accommodating varied research environments and supporting the practical adoption of chemical computing solutions.

Asia Pacific dominated the Chemical Computing Market in 2026, accounting for 34.5% of global revenue. Regional significance is supported by expanding scientific research capabilities, pharmaceutical development, and growing interest in advanced computing technologies across China, India, Japan, South Korea, Australia, Singapore, and Taiwan. Demand is influenced by the need to investigate complex molecular interactions, improve research workflows, and explore alternative computational architectures. Pharmaceutical and biotechnology research, materials science, and academic experimentation provide relevant application areas. Increasing collaboration between research institutions and technology developers can support experimentation with molecular computing, DNA computing, and other chemical-based processing methods. China contributes substantially to regional activity, while India and Japan offer important opportunities through scientific research and pharmaceutical innovation. Continued investment in research infrastructure, technical expertise, and computational capabilities strengthens the region's strategic importance. Asia Pacific's leading position reflects its substantial revenue contribution and the potential for broader adoption as experimental techniques become more practical and accessible.

North America held the second-highest regional position, representing 29.7% of revenue in 2026. The United States is a key contributor, supported by pharmaceutical research, biotechnology innovation, established scientific institutions, and advanced computational infrastructure. Canada contributes through research and technology development, while Mexico forms part of the region's broader industrial and scientific landscape. Demand is driven by interest in accelerating drug discovery, modelling molecular behaviour, and improving the analysis of complex chemical systems. Applications span pharmaceutical development, materials research, computational experimentation, and specialized scientific problem-solving. Technology adoption benefits from established research ecosystems and access to advanced software and computing resources. Collaboration among universities, biotechnology companies, and technology developers can facilitate experimentation and validation. Although commercial implementation remains dependent on technical maturity and measurable performance, North America remains strategically significant because of its research capabilities, innovation networks, and potential to translate experimental advances into practical applications.

Europe accounted for 23.8% of global revenue in 2026, establishing itself as another significant regional participant. The United Kingdom, Germany, France, Switzerland, the Netherlands, Italy, and Spain contribute through scientific research, pharmaceutical development, and industrial innovation. Demand is supported by efforts to improve molecular analysis, investigate advanced materials, and strengthen computational capabilities across research-intensive industries. Pharmaceuticals and biotechnology provide important applications, particularly where chemical modelling can complement laboratory experimentation and compound evaluation. Academic institutions and collaborative research networks also support exploration of molecular computing and related technologies. Germany's industrial research base and the region's established pharmaceutical ecosystem offer relevant foundations for adoption. However, broader commercialization depends on reproducibility, scalability, and integration with established scientific workflows. Europe's significance lies in its combination of research expertise, specialized industrial capabilities, and collaborative scientific infrastructure, which can help advance validation and practical implementation across emerging chemical computing applications.

The Middle East & Africa region represented 5.95% of revenue in 2026. Its development is linked to scientific infrastructure investment, research diversification, and growing interest in advanced technologies across Saudi Arabia, Israel, South Africa, and other regional economies. Demand opportunities include pharmaceutical research, materials investigation, chemical process analysis, and specialized computational experimentation. Saudi Arabia's research diversification initiatives and Israel's technology-oriented ecosystem provide relevant foundations for exploring emerging computing approaches, while South Africa contributes through its research and academic capabilities. Adoption may be influenced by access to specialist expertise, infrastructure availability, funding, and collaboration with established international research organizations. Molecular modelling and chemical-based processing remain potential areas of application, although commercial deployment depends on demonstrated technical feasibility. The region's strategic significance stems from opportunities to strengthen research capacity, develop specialized scientific capabilities, and incorporate emerging computational technologies into broader innovation initiatives.

Latin America accounted for 6.05% of global revenue in 2026, with Brazil serving as a key contributor alongside Argentina and other regional economies. Development opportunities are associated with pharmaceutical research, academic investigation, materials science, and industrial chemistry. Demand may increase as research organizations explore computational techniques that support molecular analysis, scientific modelling, and more informed experimental planning. Brazil's research ecosystem provides a foundation for regional participation, while Argentina contributes through scientific and academic activities. Adoption of chemical computing technologies depends on research funding, access to advanced infrastructure, specialist skills, and collaboration with international technology providers. Cloud-based resources may offer a practical route to accessing computational tools where establishing dedicated infrastructure is challenging, although suitability depends on individual research requirements. The region remains an emerging participant with opportunities to broaden its scientific applications and strengthen technological capabilities. Progress will depend on translating experimental research into reproducible, scalable solutions that address regional scientific and industrial needs.

Competition in the Chemical Computing Market is increasingly centered on differentiated software capabilities, computational accuracy, AI integration, workflow automation, and access to high-quality chemical data. Companies are strengthening their positions by combining physics-based simulations with generative and agentic AI, cloud computing, and advanced visualization. Recent collaborations demonstrate this shift, including Schrödinger’s 2026 agreement with Bristol Myers Squibb to deploy its Bunsen AI co-scientist and Evogene’s expanded collaboration with Google Cloud for AI agents in small-molecule discovery.

Geographic expansion is supported by partnerships with pharmaceutical, technology, manufacturing, and research organizations, allowing vendors to enter new markets while adapting solutions to regional research requirements. Competitive strategies increasingly include organic R&D investment, proprietary datasets, platform integration, technology partnerships, and specialized scientific services. GPU acceleration and hybrid quantum-classical computing are also becoming differentiation factors. Certifications and validated computational methods can strengthen customer confidence, particularly for regulated pharmaceutical applications, while continuous product development and strategic collaborations remain central to long-term market positioning.

The Chemical Computing market features Schrödinger, CCG, Dassault Systèmes (BIOVIA), Cadence/OpenEye Scientific, Certara, Cresset, BioSolveIT, Molecular Discovery, Optibrium, Dotmatics, ChemAxon, ACD/Labs, CDD, Simulations Plus, Scilligence, MolSoft, Jubilant Biosys, CCDC, Mestrelab Research, and KNIME. Schrödinger and CCG emphasize molecular modeling; BIOVIA combines chemistry, materials and simulation; OpenEye provides scientific software; Certara focuses biosimulation; Cresset, BioSolveIT and Molecular Discovery target structure-based discovery and virtual screening.

Optibrium advances compound design through StarDrop, AI, SAR and optimization; Dotmatics integrates chemistry R&D informatics; ChemAxon and ACD/Labs provide cheminformatics and analytical data management; CDD supports collaborative discovery data; Simulations Plus combines ADMET, PBPK and AI/ML; Scilligence adds AI-enabled informatics and robotics; MolSoft, Jubilant Biosys, CCDC, Mestrelab and KNIME extend computational chemistry, structural databases, NMR, workflow automation and analytics. Competition emphasizes cloud deployment, interoperability, validated methods, enterprise integration, partnerships and growth.The Chemical Computing market features Schrödinger, CCG, Dassault Systèmes (BIOVIA), Cadence/OpenEye Scientific, Certara, Cresset, BioSolveIT, Molecular Discovery, Optibrium, Dotmatics, ChemAxon, ACD/Labs, CDD, Simulations Plus, Scilligence, MolSoft, Jubilant Biosys, CCDC, Mestrelab Research, and KNIME. Schrödinger and CCG emphasize molecular modeling; BIOVIA combines chemistry, materials and simulation; OpenEye provides scientific software; Certara focuses biosimulation; Cresset, BioSolveIT and Molecular Discovery target structure-based discovery and virtual screening.

Optibrium advances compound design through StarDrop, AI, SAR and optimization; Dotmatics integrates chemistry R&D informatics; ChemAxon and ACD/Labs provide cheminformatics and analytical data management; CDD supports collaborative discovery data; Simulations Plus combines ADMET, PBPK and AI/ML; Scilligence adds AI-enabled informatics and robotics; MolSoft, Jubilant Biosys, CCDC, Mestrelab and KNIME extend computational chemistry, structural databases, NMR, workflow automation and analytics. Competition emphasizes cloud deployment, interoperability, validated methods, enterprise integration, partnerships and growth.

• Schrödinger, Inc.

• Chemical Computing Group ULC (CCG)

• Dassault Systèmes SE (BIOVIA)

• Cadence Design Systems, Inc. (OpenEye Scientific)

• Certara, Inc.

• Cresset

• BioSolveIT GmbH

• Molecular Discovery Ltd.

• Optibrium Ltd.

• Dotmatics

• ChemAxon

• ACD/Labs (Advanced Chemistry Development)

• Collaborative Drug Discovery (CDD)

• Simulations Plus, Inc.

• Scilligence Corporation

• MolSoft LLC

• Jubilant Biosys Ltd.

• Cambridge Crystallographic Data Centre (CCDC)

• Mestrelab Research

• KNIME AG

·         December 1, 2025 – Simulations Plus, Inc. reported FY2025 revenue of $79.2 million, up 13%, while software revenue increased 12% to $45.8 million. The company also reaffirmed FY2026 revenue guidance of $79–82 million and highlighted continued development of AI-enabled and integrated modeling solutions.

·         December 15, 2025 – BioSolveIT GmbH highlighted its 2025 product advances, including infiniSee 7.0, the launch of SYNPLE Space for automated synthesis exploration, faster chemical-space screening, and partnerships supporting automated synthesis workflows.

·         January 2026 – ACD/Labs became part of Revvity Signals Software following completion of the acquisition. The combination is intended to integrate ACD/Labs’ analytical chemistry, molecular-property prediction and informatics technologies with Revvity Signals’ scientific software portfolio.

·         February 11, 2026 – Dassault Systèmes SE (BIOVIA) reported FY2025 revenue of €6.24 billion, with recurring revenue up 6% and subscription revenue up 11%. The company also highlighted early traction for AI-powered Virtual Twins and its strategic partnership with NVIDIA to develop Industry World Models.

·         February 17, 2026 – Cadence Design Systems, Inc. (OpenEye Scientific) reported FY2025 revenue of $5.297 billion, compared with $4.641 billion in 2024. OpenEye Scientific operates within Cadence's broader computational software portfolio following its acquisition.

·         February 25, 2026 – Schrödinger, Inc. reported FY2025 revenue of $255.9 million, including $199.5 million in software revenue. The company emphasized its platform combining physics-based simulation with AI and machine learning and outlined further platform enhancements, including predictive toxicology.

·         February 26, 2026 – Certara, Inc. reported FY2025 revenue of $418.8 million, up 9%, with software revenue reaching $183.3 million. Certara also issued FY2026 revenue-growth guidance of 0–4%, reinforcing its focus on biosimulation and model-informed drug development.

·         June 16, 2026 – Cresset released Flare V12, introducing significant improvements to Free Energy Perturbation (FEP), including expanded applicability to ring-breaking transformations, faster calculations and enhanced predictive accuracy for computational drug-discovery workflows.

The Chemical Computing Market is expected to move toward increasingly integrated, AI-driven, and cloud-enabled computational workflows. Advances in generative AI, machine learning, molecular simulation, automated synthesis planning, and high-performance computing are creating opportunities across drug discovery, materials development, and chemical process optimization. Recent developments show increasing integration of AI agents with computational tools and laboratory workflows, potentially improving automation, scalability, and research productivity.

Future growth will be supported by rising pharmaceutical and biotechnology R&D, expanding chemical datasets, demand for faster molecular screening, and greater adoption of computational methods across industrial research. Emerging opportunities include physics-informed AI, machine-learned force fields, autonomous research systems, and hybrid computational approaches. However, data quality, model validation, reliability, interpretability, computational costs, and translation of digital predictions into successful laboratory outcomes remain important challenges.